WF10 Granted Full Approval By Thailand Government.MARKHAM, ONTARIO--(BUSINESS WIRE)--Sept. 15, 1997--(TSE See Tokyo Stock Exchange.
1. See Tokyo Stock Exchange (TSE).
2. See Toronto Stock Exchange (TSE). :DMX See DMX512. .) Dimethaid Research Inc. (TSE - DMX) and Oxo Chemie AG announced today that the Thailand Ministry of Public Health has granted full approval for WF10 as an immune modulator Modulator
Any device or circuit by means of which a desired signal is impressed upon a higher-frequency periodic wave known as a carrier. The process is called modulation. The modulator may vary the amplitude, frequency, or phase of the carrier. for enhancement of cell-mediated immunity cell-mediated immunity
n. Abbr. CMI
Immunity resulting from a cell-mediated immune response. Also called cellular immunity. and treatment of radiation therapy complications. As a result, WF10 will be commercially available in Thailand for patients with immune deficiencies.
"The approval of this unique immune modulation therapy by Thailand's Ministry of Public Health is a significant confirmation of the validity and efficacy of WF10 and demonstrates their concern that this treatment be immediately available to everyone who needs it," said Rebecca Keeler Keel´er
n. 1. One employed in managing a Newcastle keel; - called also keelman ltname>.
2. A small or shallow tub; esp., one used for holding materials for calking ships, or one used for washing dishes, etc. , President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Dimethaid Research. "Thailand has been exceptionally hard hit by the AIDS epidemic and we are encouraged that they have now approved this new approach to treatment," Keeler added.
"What is particularly encouraging about this approval is that it marks the first time that Thailand's Ministry of Public Health has taken the lead in approving an ethical drug," said Dr. F. W. Kuhne, President and CEO of Oxo Chemie. The approval is based upon favourable results from seven years of clinical investigations in open label studies with immune compromised patients using WF10. In a presentation at an international workshop on immune modulation in May 1997, Dr. S Dr.
dram. . Tansuphaswadikul, principal investigator in an open study conducted with HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. positive patients, stated "after six years of follow up, 89% of patients enrolled in this study who had not yet progressed to the final stage of HIV disease, were long-term non-progressors and did not develop severe opportunistic infections Opportunistic infections
Infections that cause a disease only when the host's immune system is impaired. The classic opportunistic infection never leads to disease in the normal host. or malignancies." Kuhne added, "WF10 has proven to be an exceptionally safe drug. We believe that patients will be thankful that the Thai government has recognized the success of this treatment."
WF10 has been tested in two Phase II trials in the U.S., one of which was completed in late 1995 and the other, a mechanism of action study, was completed earlier this year with the analysis currently being conducted. Results from this latest study are expected later this year.
Dimethaid Research currently owns 20 percent of Oxo Chemie and holds all distribution rights to WF10 in Canada. Dimethaid is a pharmaceutical company engaged in the development and commercialization of innovative therapeutic products which work with the body's own healing mechanisms. The Company's major product under clinical development, in addition to WF10, is PENNSAID(TM), a topical arthritis pain relief medication. Marketing approval for PENNSAID(TM) has been sought in both Canada and the United Kingdom.
CONTACT: Dimethaid Research Inc
Peter Block, 905/415-1446